Announcements - OBI Pharma 台灣浩鼎

2017.Jan.25

OBI-822 was approved to enter a Phase III clinical trial by the China Food and Drug Administration (CFDA)

2017.Jan.23

OBI Pharma Inc. announces the change of Chief Operating Officer

2017.Jan.21

Clarification on the news article by Commercial Times

2017.Jan.11

Clarification on the news article by United Daily News E-Paper

2017.Jan.10

Clarification on the news article by Economic Daily News

2017.Jan.09

Press release by the Shihlin District Prosecutors Office, Taiwan

2016.Dec.30

Announcement of the signing of a Non-Binding Letter of Intent for OBI Pharma, Inc., to issue new shares to AbProtix, Inc., in exchange for up to 70% stake in AP Biosciences

2016.Dec.22

Clarification on the news article by Economic Daily News

2016.Nov.23

OBI Pharma granted patent approval for its 2nd Generation Active Immunotherapy Treatment by Taiwan and Australia

2016.Nov.04

Clarification on the news article by Economic Daily News E-Paper

News

Latest News

Events

Latest events